New Neuroimmunology Study Results from Sheba Medical Center Described

Reposted from 4-traders
02/16/2017 | 01:02pm EDT

New Neuroimmunology Study Results from Sheba Medical Center Described (RAM-589.555 a new Polymerase-1 inhibitor as innovative targeted-treatment for multiple sclerosis)

By a News Reporter-Staff News Editor at Pain & Central Nervous System Week — Researchers detail new data in Nervous System Research – Neuroimmunology. According to news reporting originating from Ramat Gan, Israel, by NewsRx correspondents, research stated, “Targeting Polymerase-1 (POL1) transcription machinery is a new strategy for suppression of multiple sclerosis (MS) disease activity that is based on suppression of ribosomal biogenesis and subsequent activation of apoptosis.”

Financial support for this research came from Israel Ministry of Trade and Industry – Nofar – Industry Program (see also Nervous System Research – Neuroimmunology).

Our news editors obtained a quote from the research from Sheba Medical Center, “We developed an oral POL1 inhibiting compound RAM-589.555, that suppress ribosomal biogenesis as an innovative therapeutic approach to ameliorate MS. RAM-589.555 shows high permeability, specificity to POL1 pathway, ability to induce apoptosis and to inhibit proliferation and viability of activated lymphocytes both in vitro and in-vivo.”

According to the news editors, the research concluded: “Moreover, oral administration of RAM-589.555 blocks ribosomal RNA transcription and significantly suppresses and ameliorates experimental autoimmune encephalomyelitis (EAE).”

For more information on this research see: RAM-589.555 a new Polymerase-1 inhibitor as innovative targeted-treatment for multiple sclerosis. Journal of Neuroimmunology, 2017;302():41-48. Journal of Neuroimmunology can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier – www.elsevier.com; Journal of Neuroimmunology – www.journals.elsevier.com/journal-of-neuroimmunology/)

The news editors report that additional information may be obtained by contacting M. Gurevich, Sheba Med Center, Multiple Sclerosis Center, IL-52621 Ramat Gan, Israel. Additional authors for this research include R. Zilkha-Falb, R. Mashiach and M. Gurevich.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters






Scroll Up